-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PM-1015 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PM-1015 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PM-1015 in Solid Tumor Drug Details: PM-1015 is under development for...
-
Product Insights
NewRadiopharm Theranostics Ltd Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our Radiopharm Theranostics Ltd Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. Radiopharm Theranostics Ltd (Radiopharm Theranostics) develops a platform for radiopharmaceutical and nuclear medicine products for both diagnostic and therapeutic uses. The company uses its technologies including Nano-mAbs, Nano-mAbs, AVß6 Integrin, PSA-mAb, a radiopharmaceuticals platform for treating oncological diseases, HER-2, TROP-2, PD-L1. It is developing pipeline products that are in the clinical development stage including RAD101, RAD102, RAD202, RAD204, RAD301,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ABBV-1882 in Human Immunodeficiency Virus (HIV) Infections (AIDS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ABBV-1882 in Human Immunodeficiency Virus (HIV) Infections (AIDS) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ABBV-1882 in Human Immunodeficiency Virus (HIV) Infections...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FS-120 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FS-120 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. FS-120 in Solid Tumor Drug Details: FS-120 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TNT-119 in Membranous Glomerulonephritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TNT-119 in Membranous Glomerulonephritis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TNT-119 in Membranous Glomerulonephritis Drug Details: TNT-119 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – OPC-415 in Relapsed Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - OPC-415 in Relapsed Multiple Myeloma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. OPC-415 in Relapsed Multiple Myeloma Drug Details: OPC-415 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Delpacibart Etedesiran in Myotonic Dystrophy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Delpacibart Etedesiran in Myotonic Dystrophy report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Delpacibart Etedesiran in Myotonic Dystrophy Drug Details: Delpacibart etedesiran (AOC-1001)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PF-08046050 in Pancreatic Ductal Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PF-08046050 in Pancreatic Ductal Adenocarcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PF-08046050 in Pancreatic Ductal Adenocarcinoma Drug Details: PF-08046050 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PF-08046050 in Metastatic Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PF-08046050 in Metastatic Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PF-08046050 in Metastatic Colorectal Cancer Drug Details: PF-08046050 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FS-222 in Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FS-222 in Melanoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. FS-222 in Melanoma Drug Details: FS-222 is under development for the treatment...